文献速递浆细胞疾病造血干细胞移植与细胞治疗

不符合KarMMa-1试验入选标准的复发难治性多发性骨髓瘤患者接受艾基奥仑赛治疗的疗效与安全性:一项真实世界多中心研究

Efficacy and safety of idecabtagene vicleucel in patients with relapsed-refractory multiple myeloma not meeting the KarMMa-1 trial eligibility criteria: A real-world multicentre study.
PubMed 文献 · Br J Haematol · 2024-01-23

这项回顾性多中心研究评估了69例不符合KarMMa-1入选标准的复发难治性多发性骨髓瘤患者接受标准治疗艾基奥仑赛的真实世界结局。主要不符合原因包括基线3-4级血细胞减少(39%)、既往BCMA靶向治疗(26%)、肾功能损害(19%)和ECOG体能状态≥2(14.5%)。标准治疗队列的总体缓解率(93% vs 73%)和完全缓解或更好率(48% vs 33%)高于KarMMa-1,但中位无进展生存期和总生存期两组相当。

要点

  • 标准治疗队列细胞因子释放综合征发生率81%,KarMMa-1为84%。
  • 标准治疗队列免疫效应细胞相关神经毒性综合征发生率28%,KarMMa-1为18%。
  • 标准治疗队列总体缓解率93%,KarMMa-1为73%。

核心结论

  • 研究结果支持拓宽未来评估艾基奥仑赛的试验入选标准。

研究设计与样本

  • 回顾性研究,纳入来自美国三个中心的69例不符合KarMMa-1入选标准并接受标准治疗艾基奥仑赛输注的患者。

主要发现

  • 不符合KarMMa-1的主要原因为基线3-4级血细胞减少(39%)、既往BCMA靶向治疗(26%)、肾功能损害(19%)和ECOG体能状态≥2(14.5%)。
  • 标准治疗队列与KarMMa-1队列的细胞因子释放综合征发生率分别为81%和84%,免疫效应细胞相关神经毒性综合征发生率分别为28%和18%。
  • 标准治疗队列与KarMMa-1队列的早期感染(输注后≤8周)发生率分别为42%和49%,严重感染发生率分别为30%和22%。
  • 标准治疗队列与KarMMa-1队列的3-4级血细胞减少发生率分别为:中性粒细胞减少87% vs 89%,贫血51% vs 60%,血小板减少65% vs 52%。
  • 标准治疗队列的总体缓解率高于KarMMa-1(93% vs 73%),完全缓解或更好率也更高(48% vs 33%),但两组的中位无进展生存期和总生存期相当。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Ide-cel received approval for relapsed-refractory multiple myeloma based on the results of the KarMMa-1 trial. However, patients with significant comorbidities, aggressive disease and prior B-cell maturation antigen-directed therapy (BCMA-DT) were excluded. This retrospective study evaluated real-world outcomes of patients who did not meet the KarMMa-1 eligibility criteria and were treated with standard of care (SOC) ide-cel. A total of 69 patients from three US centres who did not meet the KarMMa-1 criteria underwent ide-cel infusion. The main reasons for trial ineligibility included baseline grade 3-4 cytopenia (39%), prior BCMA-DT (26%), renal impairment (19%) and Eastern Cooperative Oncology Group performance status ≥2 (14.5%). Cytokine-release syndrome occurred in 81% vs. 84%, and immune effector cell-associated neurotoxicity syndrome occurred in 28% vs. 18% of SOC versus KarMMa-1 patients, respectively. Early infection (≤8 weeks post-infusion) and severe infection rates were 42% vs. 49% and 30% vs. 22% for the SOC versus KarMMa-1 cohorts, respectively. Grade 3-4 cytopenias for SOC versus KarMMa-1 cohorts were: neutropenia (87% vs. 89%), anaemia (51% vs. 60%) and thrombocytopenia (65% vs. 52%). Overall response rate was higher for the SOC cohort (93% vs. 73%), as was the complete response or better rate (48% vs. 33%). However, median progression-free survival and overall survival were comparable between the two groups. Our findings support broadening the inclusion criteria of future trials evaluating ide-cel.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Dima D, Rashid A, Davis JA, et al. Efficacy and safety of idecabtagene vicleucel in patients with relapsed-refractory multiple myeloma not meeting the KarMMa-1 trial eligibility criteria: A real-world multicentre study. Br J Haematol. 2024. PMID: 38263627. doi:10.1111/bjh.19302

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。